These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Caffeine therapy for apnea of prematurity. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W, Caffeine for Apnea of Prematurity Trial Group. N Engl J Med; 2006 May 18; 354(20):2112-21. PubMed ID: 16707748 [Abstract] [Full Text] [Related]
6. Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. Schmidt B. Biol Neonate; 2005 May 18; 88(3):208-13. PubMed ID: 16210843 [Abstract] [Full Text] [Related]
14. Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity. Mürner-Lavanchy IM, Doyle LW, Schmidt B, Roberts RS, Asztalos EV, Costantini L, Davis PG, Dewey D, D'Ilario J, Grunau RE, Moddemann D, Nelson H, Ohlsson A, Solimano A, Tin W, Anderson PJ, Caffeine for Apnea of Prematurity (CAP) Trial Group. Pediatrics; 2018 May 18; 141(5):. PubMed ID: 29643070 [Abstract] [Full Text] [Related]
19. Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia. Bassler D, Shinwell ES, Hallman M, Jarreau PH, Plavka R, Carnielli V, Meisner C, Engel C, Koch A, Kreutzer K, van den Anker JN, Schwab M, Halliday HL, Poets CF, Neonatal European Study of Inhaled Steroids Trial Group. N Engl J Med; 2018 Jan 11; 378(2):148-157. PubMed ID: 29320647 [Abstract] [Full Text] [Related]